Unfortunately, either intrinsic or acquired resistance occurred in approximately 15-20% of ER+ HER2 negative breast cancer patients (50), with adverse effects in some patients, such as neutropenia in response to ribociclib and palbociclib (51). This evidence concerns the gene ERBB2 and breast cancer.